"Roman Candle" turns 20: Secrets of Elliott Smith's accidental masterpiece (slideshow)
Elliott and the friends with whom he recorded in middle school in Texas (photo courtesy of Dan Pickering)
“I told her no,” Kate says. “I couldn’t promise my doctor I’d make it a week. That’s how bad my life had to be before I got help. When you’re struggling to stay alive every single day, and then your doctor tells you it’s going to take two to six weeks before the medications they give you are going to work, it’s devastating.” To make matters worse, after those weeks, the drug didn’t work. Kate went through five different anti-depressants over the course of six months before confirming that none of them worked. The debilitating disorder kept her out of school for extended periods of time.
The National Center for Health Statistics estimates more than one in 10 Americans over the age of 12 took antidepressants between 2005 and 2008, the last time period for which the data are available. The rate of antidepressant use increased 400 percent from 1998 to 2008.
Traditional antidepressants go after serotonin transporter proteins. These regulatory proteins take serotonin back into the nerve cell after it has been released in the process of signaling other neurons. Antidepressants keep the transporters from performing this function.
Although nowadays, most scientists feel that serotonin release and reuptake are fairly normal in depressed patients, many scientists nonetheless believe the changes in serotonin signaling caused by antidepressants, induces the alleviation of symptoms, says Gary Rudnick, professor of pharmacology at Yale School of Medicine.
Still, antidepressants stop the process of serotonin transporters sucking up released serotonin fairly quickly, so researchers don’t understand why it takes weeks for the medications to take effect, Rudnick says. Scientists believe the behavioral effects of antidepressants may be due to other changes that occur as a reaction to the changed serotonin levels. However, researchers don’t know what reactions include, and therefore cannot create medications that target them directly.
A large portion of depression research is associated with trying to ascertain the role of neurogenesis, the process by which the brain generates new neurons. Researchers have noticed that the hippocampus of a depressed person’s brain tends to be smaller than average. Some researchers hypothesize that a problem with neurogenesiscauses both the small hippocampus as well as depression; others caution that the causal arrow may be reversed, with a small hippocampus leading to problems withneurogenesis and depression.
“Chronic [or long term] antidepressant treatment will actually increase levels ofneurogenesis,” says Julie Blendy, a neuroscientist and pharmacologist at the Perelman School of Medicine at the University of Pennsylvania. Chronic treatment will also increase levels of the protein CREB, known to play a role in the long-term effects of anti-depressants.
To test the effectiveness of CREB, Blendy got rid of the protein in mice. Of course, CREB doesn’t work in a vacuum, and another protein CREM upregulated (increased) in order to compensate for the missing CREB. Interested in the effects of CREM, Blendy upregulated CREM without touching CREB, and found the antidepressants acted much quicker. This new development, published in The Journal of Neuroscience in August 2013, suggests that identifying CREM targets would be better than attempting to identify CREB targets.
An increasingly popular antidepressant solution involves Ketamine, more popularly known as the illicit drug ‘Special K.’ Ketamine has been shown to be effective in bipolar and depressed patients who have not responded to other antidepressants. The drug works in just two hours.
The use of ketamine as an antidepressant has been called the first true development in the field of antidepressant research in 50 years, for it targets an entirely different part of the brain than traditional antidepressants. Instead of focusing on serotonin, norepinephrine or dopamine neurotransmitters, ketamine focuses on a glutamateneurotransmitter. Glutamate accounts for more than 90 percent of all synapses in the human brain, which makes it the most prevalent of all neurotransmitters.
Further studies need to be done in order to figure out how patients can use the drug without experiencing dangerous side effects, such as severe inflammation of the bladder and addiction. Abundant research also needs to be done to further Blendy’s work. Although she and her team of researchers have shown that CREM is a promising target for antidepressants, targeting that protein with a new drug will be a whole new challenge.
Heatmiser publicity shot (L-R: Tony Lash, Brandt Peterson, Neil Gust, Elliott Smith) (photo courtesy of JJ Gonson photography)
Elliott and JJ Gonson (photo courtesy of JJ Gonson photography)
"Stray" 7-inch, Cavity Search Records (photo courtesy of JJ Gonson photography)
Elliott's Hampshire College ID photo, 1987
Elliott with "Le Domino," the guitar he used on "Roman Candle" (courtesy of JJ Gonson photography)
Full "Roman Candle" record cover (courtesy of JJ Gonson photography)
Elliott goofing off in Portland (courtesy of JJ Gonson photography)
Heatmiser (L-R: Elliott Smith, Neil Gust, Tony Lash, Brandt Peterson)(courtesy of JJ Gonson photography)
The Greenhouse Sleeve -- Cassette sleeve from Murder of Crows release, 1988, with first appearance of Condor Avenue (photo courtesy of Glynnis Fawkes)
Salon is proud to feature content from Scientific American, the longest continuously published magazine in the United States and the leading popular source and authority on science, technology and innovation. With a worldwide print and digital audience of more than five million people, fourteen local language editions, and a major new
blog network, Scientific American engages, educates and inspires current and future generations of science-interested citizens and public and private sector leaders.